Skip to content
Brand AI

Tris Pharma

Recent events

Recent events tied to this brand in public sources.

Back to profile1 entries

  1. 2020

    Court upholds Quillivant XR patent validity and finds infringement

    The U.S. District Court for the District of Delaware upheld the validity of patents relating to Tris Pharma’s Quillivant XR and ruled that a generic methylphenidate product proposed by Actavis Laboratories FL would infringe those patents. The ruling prevents launch of generic versions until the patent portfolio expires in February 2031.

    Source